Almac Group Expands Asia Pacific Presence
News Jul 16, 2015
Almac Group has announced the successful completion of the Health Sciences Authority (HSA) inspection of their new Asia Pacific headquarters in Singapore.
The new facility, which officially opens on 10 July 2015, enables Almac to expand on the unique suite of clinical trial primary and secondary packaging, distribution, technology and consultation solutions offered from within the region. This allows Almac to even better serve their Asia Pacific pharmaceutical clients either conducting regional trials or expanding to international markets as well as global clients who are conducting pharmaceutical clinical trials in the region.
“Asia Pacific is a vital region for us, as currently 23% of global clinical trials for new pharmaceutical products are being conducted here. By basing our regional headquarters and operations in Singapore, we are better equipped to support our Asia-based clients in their own time zone and languages”, said Dr Robert Dunlop, President & Managing Director of Almac’s Clinical Services business unit.
Dr Dunlop continued, “With the opening of our new Singapore facility, we are directly supporting studies run by regional and global pharmaceutical firms by providing critical manufacturing, packaging, supply chain management and Interactive Response Technology (IRT) support services in Asia Pacific.”
“We welcome Almac’s investment into the vibrant ecosystem of biomedical sciences companies in Singapore,” said Mr. Kevin Lai, Executive Director of Biomedical Sciences and Consumer Businesses, Singapore Economic Development Board (EDB). “Their decision reinforces Singapore’s reputation as a preferred location where companies manage their clinical development and supply chain management for the region and beyond.”
The Health Sciences Authority (HSA) inspection of the new facility ensuring standards of safety, quality and efficacy will make Almac the first full service clinical trial packaging and distribution organization to ever receive GMP certification. This facility strengthens the Group’s global footprint with facilities in Europe, the US and Singapore, as well as satellite offices in Japan.
The Singapore facility has full-service equipment which includes primary packaging rooms, secondary packaging areas, frozen storage, label control room, a Just-in-Time (JIT) labelling suite and non-GMP storage area offering clients in the region a streamlined, personalized, turnkey solution which ultimately optimizes their clinical trial.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019